Congress file hr2821-119, before Congress. Still to be decided as of 2026-07-20.
Latest action: Motion to reconsider laid on the table Agreed to without objection.
Drug companies get new options for required safety tests The FDA must update its rules within one year to let drug makers use lab-based tests and computer models instead of animal testing when they seek permission to test new drugs on people.
Could speed up drug development and lower some testing costs If lab tests work faster than animal studies, new medicines might reach patients sooner; lab testing is also often cheaper, which could help smaller drug companies afford safety testing.
Lab tests must still work as well as animal data The FDA has not yet confirmed that all lab tests and computer models can replace animal testing for every type of drug, so safety gaps could emerge if a lab test misses something an animal study would have caught.
This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
Read the official record for hr2821-119
See everything up for a vote · This week in Congress · See what we have filed with the clerk